Direct Biologics LLC, a manufacturer of regenerative medical products, reported on Tuesday the receipt of US FDA expanded access for ExoFlo to treat patients with COVID-19 associated acute respiratory distress syndrome (ARDS) under its national multi-centre, Phase II, placebo controlled, randomized clinical trial (EXIT COVID-19).
Under the expanded access protocol, the company said it will make ExoFlo available to a broader group of patients with severe COVID-19, many of whom would not meet acceptance criteria for EXIT COVID-19, often under conditions of "compassionate use."
ExoFlo is an investigational new drug that has not been approved or licensed by FDA. It is an extracellular vesicle product isolated from human bone marrow mesenchymal stem or stromal cells (MSCs). ExoFlo provides natural bioactive signals that have been shown to modulate inflammation and direct cellular communication, added the company.
This US FDA expanded approval protocol follows multiple approvals for single patient Emergency Investigational New Drug (eIND) applications granted in September and October. The emergency INDs are a mechanism by which physicians can obtain rapid approval to administer medication to a single patient through a direct appeal to the FDA, Direct Biologics concluded.
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
Merck finalises acquisition of Harpoon Therapeutics Inc
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
Nuvalent's NVL-520 receives FDA breakthrough therapy designation
Dassault Systèmes enhances patient care with virtual twin experience at Paris hospital
Pulmonx initiates CONVERT II trial for AeriSeal System in COPD treatment
Priority Review of Dupixent underway by FDA for COPD treatment
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
AstraZeneca reports positive resultsfor Tagrisso in Stage III lung cancer trial
AstraZeneca announces US acceptance of BLA for datopotamab deruxtecan to treat lung cancer
Erasca agrees clinical trial deal with Novartis to study naporafenib in combination with trametinib
FDA accepts Bristol Myers Squibb's Augtyro application for Priority Review